Biomarker Core

生物标志物核心

• 批准号: 10615171
• 负责人: Robert A Rissman
• 金额: $ 23.22万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10615171
• 关键词: Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-42; Amyloid beta-Protein; Anatomy; Biochemical; Biological Assay; Biological Markers; Biological Specimen Banks; Blood; Blood Vessels; Brain; Brain imaging; Calibration; Cerebrospinal Fluid; Clinical; Clinical Trials; Collaborations; Collection; Computer Analysis; DNA; DNA analysis; Data; Data Set; Dedications; Dementia; Development; Diagnosis; Diffusion Magnetic Resonance Imaging; Disease; Disease model; Education; Ensure; Fostering; Genetic; Genomics; Genotype; Goals; Heterogeneity; Hippocampus; Human; Image; Informatics; Infrastructure; Instruction; International; Lesion; Ligand Binding; Link; Liquid substance; Magnetic Resonance Imaging; Measurement; Measures; Methods; Modality; Molecular; Nerve Degeneration; Onset of illness; Other Genetics; Participant; Pathologic; Pathology; Phenotype; Plasma; Positron-Emission Tomography; Practice Guidelines; Procedures; Prognosis; Prognostic Marker; Protocols documentation; Quality Control; Research; Research Personnel; Research Project Grants; Research Support; Resources; Restriction Spectrum Imaging; Risk; Sampling; Scanning; Scientist; Serum; Specimen; Staging; Standardization; TREM2 gene; Techniques; Testing; Time; Training; Translational Research; Ventricular; Work; alpha synuclein; biobank; biomarker discovery; career development; cell repository; clinical translation; cohort; comorbidity; connectome; data management; diagnostic accuracy; diagnostic biomarker; genetic variant; genome-wide analysis; hazard; image archival system; imaging biomarker; imaging modality; improved; industry partner; interest; magnetic resonance imaging biomarker; meetings; microbiome analysis; neuroimaging; neuropathology; novel; novel diagnostics; novel marker; outreach; phenotypic biomarker; phenotypic data; pre-clinical; programs; recruit; stool sample; tau Proteins; tau-1; therapy development; white matter

BIOMARKER CORE SUMMARY/ ABSTRACT In this renewal application, we will add a Biomarkers Core to the existing infrastructure of the UCSD ADRC. Since its inception in 1984, the UCSD ADRC has committed to developing a robust collection of biofluids and neuroimages from the cohort which have been integrated into the Neuropathology and Clinical Cores, respectively. With the needs of our program and research increasing and the instructions of this RFA, we are establishing a dedicated Biomarkers Core to manage, analyze and share ADRC biofluids and images and their related datasets. We anticipate that our fluid and imaging resources will greatly aid in identifying new mechanisms underlying dementia. We propose 5 Aims of the Biomarkers Core: 1) Biofluid and image collection using established SOPs and best practice guidelines; 2) Perform standardized biomarker analyses on CSF and imaging, including Aβ and tau levels, APOE and TREM2 genotyping, hippocampal, cortical and ventricular volumes and analysis of Aβ and tau PET scans; 3) Develop a state of the art biobank and imaging dataset to support research nationally and internationally; 4) Develop and maintain a state of the art biofluid and imaging repository to provide the ADRC projects and other investigators with well characterized including early AD and MCI cases; 5) Foster the utilization of the ADRC Biofluids and images for new research and inter-center collaborations. With the ADRC Outreach, Recruitment and Education (ORE) Core organize meetings to encourage the use of the biomarkers core. We will continue to provide DNA to local and national investigators and for multi-center initiatives such as NCRAD and the Genome-Wide Analysis Studies organized by NIA.

生物标志物核心总结/摘要 在此更新申请中，我们将在UCSD ADRC的现有基础设施中添加生物标志物核心。 自1984年成立以来，UCSD ADRC一直致力于开发强大的生物流体收集， 已整合到神经病理学和临床核心中的来自队列的神经图像， 分别随着我们的计划和研究的需求不断增加，以及RFA的指示，我们 建立一个专门的生物标志物核心，以管理，分析和共享ADRC生物流体和图像及其 相关数据集。 我们预计，我们的流体和成像资源将大大有助于确定潜在的新机制， 痴呆我们提出了生物标志物核心的5个目标：1）使用已建立的生物流体和图像收集 SOP和最佳实践指南; 2）对CSF和成像进行标准化生物标志物分析， 包括Aβ和tau水平，APOE和TREM 2基因分型，海马、皮质和心室体积， Aβ和tau PET扫描分析; 3）开发最先进的生物库和成像数据集，以支持 国内和国际研究; 4）开发和维护最先进的生物流体和成像 存储库，为ADRC项目和其他调查人员提供良好的特征，包括早期AD， MCI病例; 5）促进ADRC生物液体和图像用于新研究和中心间研究 合作。 与ADRC外联，招聘和教育（ORE）核心组织会议，鼓励使用 生物标志物的核心。我们将继续为当地和国家研究人员以及多中心研究人员提供DNA。 NIA组织的NCRAD和全基因组分析研究等倡议。